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Type 2 diabetes mellitus (T2DM) is an established risk factor for cardiovascular and nephro-
pathic events. In the Netherlands, prevalence of T2DM is expected to be as high as 8% by
2025. This will result in significant clinical and economic impact, highlighting the need for
well-informed reimbursement decisions for new treatments. However, availability and con-
sistent use of costing methodologies is limited.
Objective
We aimed to systematically review recent costing data for T2DM-related cardiovascular and
nephropathic events in the Netherlands.
Methods
A systematic literature review in PubMed and Embase was conducted to identify available
Dutch cost data for T2DM-related events, published in the last decade. Information
extracted included costs, source, study population, and costing perspective. Finally, papers
were evaluated using the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS).
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Results
Out of initially 570 papers, 36 agreed with the inclusion criteria. From these studies, 150
cost estimates for T2DM-related clinical events were identified. In total, 29 cost estimates
were reported for myocardial infarction (range: €196-€27,038), 61 for stroke (€495-
€54,678), fifteen for heart failure (€325-€16,561), 24 for renal failure (€2,438-€91,503), and
seventeen for revascularisation (€3,000-€37,071). Only four estimates for transient ischae-
mic attack were available, ranging from €587 to €2,470. Adherence to CHEERS was gener-
ally high.
Conclusions
The most expensive clinical events were related to renal failure, while TIA was the least
expensive event. Generally, there was substantial variation in reported cost estimates for
T2DM-related events. Costing of clinical events should be improved and preferably stan-
dardised, as accurate and consistent results in economic models are desired.
Introduction
Type 2 diabetes mellitus (T2DM) is an established risk factor for vascular complications, car-
diovascular events and renal failure [1,2]. Also, T2DM is the most prevalent chronic disease in
the Netherlands. In 2014, an estimated 960,000 patients with T2DM were known to the general
practitioner, which is about 5.7% of the Dutch population [3,4]. The prevalence is expected to
be as high as 8% in the year 2025 [5]. Besides significant clinical impact, this will result in pro-
found increases in healthcare expenditures and highlights the need for appropriate assessment
of T2DM drugs’ cost-effectiveness and well-informed reimbursement decisions.
T2DM treatment is aiming to normalise blood sugar levels, blood pressure and lipids with
the ultimate goal to prevent cardiovascular and renal complications. Major cardiovascular
complications include myocardial infarction (MI), stroke, transient ischaemic attack (TIA),
heart failure (HF), and revascularisation. Major renal complications include end-stage renal
disease (ESRD), dialysis, and kidney transplantation. Given their significant impact on both
patients’ health status as well as healthcare expenditures, a prerequisite for state-of-the-art
health-economic evaluations is the full understanding and consistent use of T2DM-related
complications’ costs, especially those of related cardiovascular and nephropathic events.
In the Netherlands, the National Health Care Institute (Zorginstituut Nederland, ZIN) pro-
vides guidelines for pharmacoeconomic research, highlighting key methodological issues that
should be addressed for an adequate economic evaluation [6]. For instance, according to the
guideline, economic evaluations should be carried out using a societal perspective, taking into
account costs both inside and outside the healthcare system, and thus including e.g. productiv-
ity losses. Indeed, according to pharmacoeconomic guidelines, costs for clinical events are
essential for designing adequate and valid health-economic models [6,7]. Yet, availability, a
standardised measurement, and consistent use of costs of clinical events related to T2DM is
limited. Here, we aim to systematically review available recent costing data for T2DM-related
major cardiovascular and nephropathic events in the Netherlands.
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Methods
Study design
A systematic literature review was conducted to identify all available publications specifying
Dutch costs for clinical events commonly found in T2DM patients. This review was reported
according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) literature review methodology [8], provided in S1 Table.
Search strategy
The PubMed database was searched for publications between January 1st 2005 and January 1st
2018. An overview of keywords can be found in Table 1. In addition, reference lists of identi-
fied reviews and meta-analyses on the topic were searched for potentially relevant articles.
Subsequently, Embase was also searched with adapted keywords from Table 1, correspond-
ing with Emtree terms. In this analysis, results also found in MEDLINE were filterred out, as
to improve efficiency.
In- and exclusion criteria
Articles were included in this review if they met the following criteria:
The papers considered direct costs for the specified clinical events per patient in the
Netherlands.
Papers required to be published between January 1st 2005 and January 1st 2018, to reflect
recent data only, as older estimates may be “outdated” and irrelevant for present day.
The paper evaluated at least one of the six predefined major clinical events (MI, stroke,
TIA, HF, renal failure, and revascularisation).
Papers included T2DM patients or patients with clinical events commonly associated with
T2DM. It should be noted that these clinical events are not restricted to T2DM patients and
can occur in patients without T2DM as well. Therefore, given the focus on the costs for these
clinical events, the patients in the included studies were not always T2DM patients.
The full-text of the paper required to be accessible.
Articles reflecting guidelines or study protocols, meeting reports, or case reports were
excluded.
Extracted information
Direct medical costs, such as those for hospitalisation, medication and rehabilitation, were
included. Additionally, and in line with the Dutch preferred societal perspective, indirect costs
such as productivity losses were identified and included. If comparative studies were identi-
fied, the costing in the standard-of-care arm was chosen to be included, as it reflects standard
of practice more accurately. Next to costs, data extracted included the cost source, study popu-
lation, and the costing perspective (e.g. a healthcare payer, the hospital or the society).
Table 1. Search terms used to identify studies reporting on Dutch type 2 diabetes mellitus clinical event costs.
Domain Search terms
Subject “costs and cost analysis” OR “cost-effectiveness” OR “cost-utility” OR “cost-benefit” OR “cost-effective”
OR “economic evaluation” OR “economic analysis”
Events “diabetes mellitus” OR “stroke” OR “myocardial infarction” OR “heart failure” OR “ischemic attack,
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Analyses
Studies were categorised per clinical event, i.e., MI, stroke, TIA, HF, revascularisation, and
renal failure. Subsequently, they were further sorted by year of costing, i.e. the price date, were
reported. Cost estimates included the acute costs for the event, and, if available, cost for fol-
low-up (monthly or annual, depending on availability). These analyses were of a descriptive
nature, as only a limited number of cost estimates were trial-based, limiting generalisability.
To ease comparison, we also reported maximum and minimum annual costs in 2018 euros,
with standard Dutch inflation rates used for standardising costs from previous years [9].
For papers that were health economic evaluations, adherence to the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) was also assessed to put the individual
cost estimates into perspective, regarding time horizon, reporting perspective, et cetera [10].
Results
Search results
The results of the systematic literature search are displayed in the flowchart in Fig 1.
Overview
In total, 36 studies met our inclusion criteria. From these studies, 150 cost estimates for clinical
events related to T2DM were identified. All papers provided the year of costing, except for
three [11–13]. For the first two studies, the year of costing was assumed to be the year before
their respective publication, while for the latter, the year of costing was found in one of its
references.
Table 2 provides the characteristics of the included studies. Nineteen analyses took a health-
care payer perspective, seven a societal perspective, six a hospital perspective, one a third-party
payer perspective, and three articles did not specify the perspective used. Of all studies, eight
explicitly stated that in addition to direct costs, indirect costs were also taken into account
[1,12,14–19]. Four of these studies took productivity losses into account, and these four all
used a societal perspective [1,14,16,18]. The other four studies took overhead costs into
account, although these are not considered indirect costs in health economics.
Five studies used the Diagnosis Treatment Combination (Diagnose Behandel Combinatie,
DBC), the Dutch case-mix categorisation aligned with resource use and applied for reimburse-
ment of hospitals [20–24]. These DBCs are comparable with diagnosis related group (DRG)
based systems used in other countries, although certain differences do exist, such as goal and
scope [25]. In three studies, information on resource use was gathered from the EDISSE trial
[13,26,27], while the sources for the other papers concerned registries, case record files, cost
diaries, trials, billing systems, or cost estimates from older costing studies.
The Dutch Manual for Costing in Economic Evaluations was referenced by eighteen studies
(62%), eleven of which used the manual to derive standard prices. Tariffs provided by the
Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa) were used in four studies
[20,23,28,29]. Furthermore, nine articles gathered unit costs from hospitals directly. Fourteen
studies used at least one costing study to derive their cost estimates from. Of these fourteen
studies, it was found that nine referenced at least one paper published before 2005, and four
references reported their costs in Dutch guilders. The cost estimates derived from one paper
were reported in 2002 US dollars [30]. These estimates were converted to 2002 euros, using an
exchange rate of 1 EUR = 0.95 USD [31].
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Costs for clinical events related to T2DM
Considerable variation among the reported costs was found. Fig 2 shows the minimum and
maximum costs per clinical event, represented in 2018 EUR. Cost details for each clinical
event are specified in sections 3.3.1 to 3.3.6, and overviews are provided in Tables 3–8.
Myocardial infarction
In seventeen studies, 29 different cost estimates for MI were used, with costs calculated
between 1999 and 2015 (Table 3). The papers used various methods to derive cost estimates,
such as hospital database analyses, and expert opinions. It was possible to make a differentia-
tion between first-year (acute) and follow-up costs. Seven studies also considered the follow-
Fig 1. Flow chart of literature search.
https://doi.org/10.1371/journal.pone.0221856.g001
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Table 2. Characteristics of included studies.
Study Type of
study




1 Adarkwah et al.
2011 [32]
Modelling Patients newly diagnosed with
T2DM
ACE-inhibitor Renal failure Healthcare
payer
2 Anastasiadis et al.
2013 [11]
Modelling Patients undergoing CABG Extracorporeal circulation Revascularisation Healthcare
payer
3 Baeten et al. 2010
[26]
Modelling Hospitalised stroke patients Stroke services Stroke Healthcare
payer
4 Boersma et al. 2006
[33]





5 Boersma et al. 2010
[34]
Modelling Patients with elevated albuminuria
levels
Various population-based screen-and-treat





6 Boyne et al. 2013
[35]
Modelling Patients with heart failure Telemonitoring analysis HF Healthcare
payer
7 Buisman et al. 2015
[20]






8 De Vries et al. 2014
[36]






9 Greving et al. 2011
[28]






10 Heeg et al. 2007
[37]





11 Heyde et al. 2007
[12]
Trial Patients receiving PCI Short-term observation after procedure Revascularisation Hospital
12 Hofmeijer et al.
2013 [21]
Modelling Stroke patients aged 60 years or
younger
Surgical Decompression Stroke Healthcare
payer
13 Hunt et al. 2017
[24]
Modelling Patients with T2DM uncontrolled
on basal insulin






14 Jacobs et al. 2018
[38]
Modelling Patients 65 years and over receiving
seasonal influenza vaccination










16 Mazairac et al. 2013
[14]
Modelling Patients with ESRD Hemodiafiltration Renal failure Societal
17 Nathoe et al. 2005
[39]




18 Osnabrugge et al.
2015 [40]
Modelling Patients with three-vessel or left
main CAD
PCI vs. bypass surgery Revascularisation Healthcare
19 Peltola et al. 2013
[22]
- Stroke patients n.a. Stroke Hospital
20 Ramos et al. 2017
[41]
Modelling Patients with chronic heart failure







21 Roze et al. 2016 [29] Modelling Patients with T2DM uncontrolled








Costs of clinical events in T2DM patients in the Netherlands: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0221856 September 6, 2019 6 / 22
up costs after year one [1,24,28,29,36,37,43]. For patients with MI, the average costs in the first
year ranged from €3,390 to €27,038 per patient. The costs accrued in the subsequent years ran-
ged between €1,026 and €2,092 per patient per year. The studies that defined which direct
costs were covered only took hospitalisation costs into account, ergo no rehabilitation or other
costs were covered. Three papers also included indirect costs, though only one accounted for
productivity losses [1], as the other two included only overheads [15,17].
Stroke
The majority of papers reported cost estimates for stroke events: 61 cost estimates in 22 studies
were identified (Table 4). The year of costing ranged from 1999 to 2015. Four papers reported
on the different severities of stroke [16,28,38,42], and four papers mentioned the type of stroke
studied: four reported on ischaemic strokes specifically [16,20,38,47], while one reported hae-








22 Soekhlal et al. 2013
[23]
Costing Patients hospitalised for acute MI n.a. MI Not specified
23 Stevanović et al.
2014 [42]




24 Struijs et al. 2006
[27]
Modelling Stroke patients n.a. Stroke Not specified
25 Tan et al. 2009 [15] Costing n.a. n.a. - MI
- Stroke
Hospital
26 Tholen et al. 2010
[16]
Modelling Patients with recent TIA or minor
ischaemic stroke
CT angiography Stroke Societal
27 Tiemann 2008 [17] Modelling Healthy males between 50 and 60 n.a. MI Hospital
28 Vaidya et al. 2014
[43]
Modelling Suspected cardiac chest pain patients several MI Healthcare
payer
29 Van Eeden et al.
2015 [18]
Trial Patients post-stroke n.a. Stroke Societal
30 Van Exel et al. 2005
[13]
Trial Stroke patients Stroke services Stroke Healthcare
payer
31 Van Genugten et al.
2005 [44]
Trial Patients with acute MI HF and
LVSD
Eplerenone HF Societal
32 Van Giessen et al.
2016 [45]
Modelling Patients with T2DM aged 60 years
and over
Screening strategies to detect HF in T2DM
patients
HF Healthcare
33 Van Haalen et al.
2014 [1]







34 Van Mastrigt et al.
2006 [19]
Trial Low-risk CABG patients Short-stay IC (8h of IC treatment) Revascularisation Hospital
35 Vemer et al. 2010
[46]
Modelling Smoking individuals Smoking cessation Stroke Healthcare
payer
36 Verhoef et al. 2014
[47]
Modelling Patients with AF, age 70, initiating
oral anticoagulant therapy





ACE angiotensin-converting enzyme, AF atrial fibrillation, CABG coronary artery bypass grafting, CAD coronary artery disease, CSII continuous subcutaneous insulin
infusion, CV cardiovascular, CT computed tomographic, HF heart failure, IC intensive care, LVSD left ventricular systolic dysfunction, MDI multiple daily injections,
MI myocardial infarction, n.a. not applicable, PCI percutaneous coronary intervention, T2DM type 2 diabetes mellitus, TIA transient ischaemic attack
https://doi.org/10.1371/journal.pone.0221856.t002
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separated over two periods of six months[18,26,37,42]. One paper reported cost estimates per
3-month cycles [38], and another for just the first six months [13]. Two studies showed that
the majority of the cost estimates for stroke events were made up by hospital stay [15,20].
When rehabilitation was considered, it made up an even larger share than hospital stay
[18,21]. Three studies also included indirect costs [1,15,18]. Although Tholen et al. did take
indirect costs into account, the cost estimate in Table 4 does not include productivity losses,
since the study reported them separately [16].
Transient ischaemic attack
Four different costs for TIA were reported in three different studies, with the lowest cost esti-
mate being €587, and the highest amounting to €2,470, reflecting inpatient and outpatient
costs, respectively [20]. Hospital stay accounted for the largest share of the costs; €1,748 of the
€2,470 were for inpatient stay [20].
Heart failure
A total of fifteen cost estimates for heart failure were reported in eight studies (Table 6).
The costs for heart failure varied between €945 and €16,561 per patient per year. One study
reported a cost estimate for fatal congestive heart failure (HF), which was assumed to be 50%
of non-fatal congestive HF events [1]. Three papers reported estimates for the subsequent
Fig 2. Costs for T2DM-related events in 2018 euros. CABG coronary arterial bypass grafting, ESRD end-stage renal disease, HF heart failure, MI myocardial infarction,
PCI percutaneous coronary intervention, TIA transient ischaemic attack, T2DM type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pone.0221856.g002
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years of congestive HF [1,24,29]. These ranged between €325 and €6,672. One study reported
separate costs for different severities of HF, whether HF went undetected, and by sex [45]. The
main cost driver for heart failure is hospital stay, both for the first year as well as the follow-up
years, where rehospitalisation accounted for 73% of the costs [44].
Renal failure
A total of 24 cost estimates associated with renal failure were reported in seven studies
(Table 7). Several different types of dialysis were covered in five papers [14,24,29,32,34],
reporting fifteen cost estimates in total, which ranged between €54,067 and €89,447. The cost
estimates for dialysis in subsequent years were reported to be equal to the estimates for the first
year. Three studies reported five cost estimates on renal transplantation [24,29,32]. First year
cost estimates ranged between €14,387 and €91,503, and costs for subsequent years were esti-
mated at €2,438 and €3,680. Four cost estimates for end-stage renal disease (ESRD) were
reported in three studies [1,32,41]. These costs ranged between €3,640 and €69,440. Adarkwah
et al. calculated a weighed mean for ESRD patients, taking renal transplantation and different
Table 3. Summary of studies reporting costs for myocardial infarction.
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in €
(year)
Source(s) Unit cost year 2+ in €
(year)
Source(s) Direct costs Indirect costs
Hunt et al. [24] Acute MI €6,341 (2015) [23] €1,026 (2015) [23] ✓
Ramos et al. [41] Acute MI €3,390 (2015) Not specified ✓ ✓
Jacobs et al. [38] Acute MI €5,021a (2014) [23] ✓
Post MI €280a (2014) [23] ✓
Roze et al. [29] Acute MI €5,138 (2013) [36] €1,932 (2013) [36] ✓
Stevanović et al.
[42]
Acute MI €5,021 (2013) [23] ✓
Monthly
maintenance
€196 (2013) [28] ✓
De Vries et al. [36] Acute MI €5,012 (2012) [23] €1,885 (2012) [48] ✓
Soekhlal et al. [23] Acute MI €5,021 (2012) [17,49], DMC,
tariffs
✓
Vaidya et al. [43] Acute MI €12,446 (2012) [50] €2,092 (2012) [50] ✓
Verhoef et al. [47] Acute MI €5,021 (2012) [28] ✓
Van Haalen et al.
[1]
MI €27,038 (2011) [28,51] €1,132b (2011) [28] ✓ ✓
Fatal MI €9,094 (2011) Assumption ✓
Greving et al. [28] Acute MI €17,342 (2008) [52,53] €1,054 (2008) [52,53] ✓
Tan et al. [15] Acute MI €5,338 (2005) Hospital ✓ ✓
Tiemann [17] Acute MI €5,599 (2005) Hospital ✓ ✓
Heeg et al. [37] First 6 months €10,250 (2004) [52,54] €1,750 (2004) [52,54] ✓
Second 6 months €2,500 (2004) [52,54] ✓
Fatal MI €1,500 (2004) [52,54] ✓
Kauf et al. [30] Acute MI €7,128c (2002) Analysts ✓
Boersma et al. [33] Acute MI €5,823 (1999) iMTA ✓
Nathoe et al. [39] MI €12,395 (1999) [55] ✓
CV cardiovascular, DMC Dutch manual of costing, iMTA Institute for Medical Technology Assessment, MI myocardial infarction
a Costs reported per 3-month cycles
b No indirect costs applied to follow-up costs, since friction cost method was used for indirect costs
c Study reported cost estimates in 2002 USD, converted to 2002 EUR for presentation in the table
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Table 4. Summary of studies reporting costs for stroke.
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in €
(year)






Hunt et al. [24] Stroke €24,142 (2015) [20] €1,968 (2015) [20] ✓
Fatal stroke €5,523 (2015) [20] ✓
Jacobs et al. [38] Acute minor IS €19,146a (2014) [26] ✓
Post minor IS €1,484a (2014) [26] ✓
Acute major IS €44,138a (2014) [26] ✓
Post major IS €3,958a (2014) [26] ✓
Fatal IS €11,178a (2014) [56] ✓
Acute HS €24,292a (2014) [26] ✓
Post HS €1,691a (2014) [26] ✓
Fatal HS €6,037a (2014) [56] ✓
Roze et al. [29] Stroke €13,819 (2013) [36] €1,932 (2013) [36] ✓
Fatal stroke €8,603 (2013) [36], tariffs ✓
Stevanović et al.
[42]
Mild stroke, first 6 months €16,097 (2013) [26] €1,174b (2013) [26] ✓
Mild stroke, second 6
months
€4,470 (2013) [26] ✓
Moderate stroke, first 6
months
€44,640 (2013) [26] €8,749b (2013) [26] ✓
Moderate stroke, second 6
months
€21,146 (2013) [26] ✓
Severe stroke, first 6
months
€54,678 (2013) [26] €11,178b (2013) [26] ✓
Severe stroke, second 6
months
€26,711 (2013) [26] ✓
Fatal stroke €2,988 (2013) [28]
Buisman et al.
[20]
IS, inpatient €5,328 (2012) DMC, DBC, tariffs ✓
IS, outpatient €495 (2012) DMC, DBC, tariffs ✓
De Vries et al.
[36]
Stroke €13,480 (2012) Not accessible €1,885 (2012) [48] ✓
Van Eeden et al.
[18]
Stroke, first 6 months €21,731 (2012) Bottom-up costing,
DMC
✓ ✓
Stroke, second 6 months €7,711 (2012) Bottom-up costing,
DMC
✓ ✓
Verhoef et al. [47] IS €19,652 (2012) [27]
Van Haalen et al.
[1]
Stroke €45,430 (2011) [26,57] €4,497c (2011) [26] ✓ ✓
Fatal Stroke €17,799 (2011) Assumption ✓
Hofmeijer et al.
[21]





CV event €7,047 (2008) [56] ✓
Fatal CV event €1,593 (2008) [56] ✓
Greving et al. [28] Major stroke €36,173 (2008) [53] €21,122 (2008) [53] ✓
Minor stroke €6,343 (2008) [53] €1,085 (2008) [53] ✓
Peltola et al. [22] Stroke €5,262 (2008) DBC ✓
Tholen et al. [16] Major IS €43,650 (2007) [58] €25,487 (2007) [58] ✓
Minor IS €7,654 (2007) [58] €1,310 (2007) [58] ✓
Vemer et al. [46] Stroke €23,119 (2006) [27] €5,229 (2006) [27] ✓
(Continued)
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types of dialysis into account [32]. The costs for one year of ESRD were estimated at €42,219,
while one year of dialysis and renal transplantation cost €79,112 and €14,387, respectively.
Revascularisation
A total of seventeen cost estimates for revascularisation were reported in nine studies
(Table 8). Two types of revascularisation were assessed; percutaneous coronary intervention
(PCI) and coronary arterial bypass grafting (CABG), with respectively ten and seven cost esti-
mates identified. PCI cost estimates ranged from €3,000 to €14,037 [37,40]. For CABG, the
cost estimates ranged between €5,441 and €18,010 [33,40].
Adherence of papers to CHEERS
Table 9 presents the results of the papers that were assessed according to the CHEERS guide-
line. Overall, papers’ adherence to the checklist was found to be high, even though articles did
Table 4. (Continued)
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in €
(year)






Tan et al. [15] Stroke €6,264 (2005) Bottom-up costing,
hospitals
✓ ✓
Heeg et al. [37] Stroke, first 6 months €17,750 (2004) [59] €4,500 (2004) [59] ✓
Stroke, second 6 months €6,750 (2004) [59] ✓
Fatal Stroke €3,250 (2004) [59] ✓
Baeten et al. [26] Stroke, first 6 months €24,837 (2003) [60], DMC €4,173b (2003) Not
accessible
✓
Stroke, second 6 months €9,826 (2003) [60], DMC ✓
Struijs et al. [27] Stroke €21,948b (2000) [55,60] €4,993d (2000) [55,60] ✓
Boersma et al.
[33]
Stroke €5,404 (1999) iMTA ✓
Nathoe et al. [39] Stroke €7,748 (1999) [55] ✓
Van Exel et al.
[13]
Stroke, first 6 months €16,000 (1999) [60] ✓
DBC diagnosis treatment combination, DMC Dutch manual of costing, HS haemorrhagic stroke, iMTA Institute for Medical Technology Assessment, IS ischaemic
stroke
a Costs reported per 3-month cycles
b This cost estimate is a weighted mean calculated using the ratio between sexes as reported in the paper.
c No indirect costs applied to follow-up costs, since friction cost method was used for indirect costs
d Multiple cost estimates were reported, specified for gender and age, these values were based on women between the age of 75 and 84.
https://doi.org/10.1371/journal.pone.0221856.t004
Table 5. Summary of studies reporting costs for TIA.
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in € (year) Source(s) Unit cost year 2+ in € (year) Source(s) Direct costs Indirect costs
Ramos et al. [41] TIA €807 (2015) Not specified ✓ ✓
Buisman et al. [20] TIA, inpatient €2,470 (2012) DMC, DRG ✓
TIA, outpatient €587 (2012) DMC, DRG ✓
Verhoef et al. [47] TIA €949 (2012) [61] ✓
DMC Dutch manual of costing, DRG diagnosis related group, TIA transient ischaemic attack
https://doi.org/10.1371/journal.pone.0221856.t005
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not explicitly state whether a reporting guideline was used. The items with the lowest amount
of adherence were measurement and valuation of preference-based outcomes, assumptions,
and characterising heterogeneity. Assumptions were not clearly defined in five studies




In this systematic review, we aimed to outline the Dutch cost estimates of six-major T2DM-
related clinical events. It was found that many studies reported on cost estimates for MI and
stroke, but only a limited number focussed on other T2DM-related clinical events. The most
expensive clinical events were found to be related to renal failure, most notably ESRD and dial-
ysis, although some estimates reported stroke and CABG to be a significant source of expendi-
tures as well. MI, TIA, and HF were generally among the least expensive T2DM complications.
A large variety in cost estimates was found in the included studies. Adherence to CHEERS
guidelines was generally high.
Interpretation
While some heterogeneity is to be expected when dealing with estimates, most values showed
poor agreement, sometimes even between a study and its reference. For example, Verhoef
et al. reported cost estimates for TIA, but this value was considerably lower than the cost esti-
mates found in their sources [47,61].
Three studies reported cost estimates for stroke separated into minor and major stroke
[16,28,38]. In 2018 EUR-corrected values, minor stroke was estimated to cost €9,079, €7,342,
and €24,557, respectively, during the first year of stroke and €1,554, €1,256, and €6,177 in
Table 6. Summary of studies reporting costs for heart failure.
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in € (year) Source(s) Unit cost year 2+ in € (year) Source(s) Direct costs Indirect costs
Hunt et al. [24] Congestive HF €5,479 (2015) [62] €954 (2015) [62] ✓
Ramos et al. [41] HF €945 (2015) Not specified ✓ ✓
Roze et al. [29] Congestive HF €2,870 (2013) Tariffs €325 (2013) Tariffs ✓
Van Haalen et al. [1] Congestive HF €15,571 (2011) [63,64] €6,762a (2011) Assumption ✓ ✓
Fatal congestive
HF
€3,349 (2011) Assumption ✓
Van Giessen et al. [45] NYHA I €1,459b (2011) [65] ✓
NYHA II €1,721b (2011) [65] ✓
NYHA III €2,650b (2011) [65] ✓
NYHA IV €7,156b (2011) [65] ✓
Boyne et al. [35] HF €16,561 (2008) DMC,
hospital
✓
Van Genugten et al.
[44]
HF post-MI €5,232 (2003) Actual costs ✓
Boersma et al. [33] HF €4,795 (1999) iMTA ✓
DMC Dutch manual of costing, HF heart failure, iMTA Institute for Medical Technology Assessment, MI myocardial infarction, NYHA New York Heart Association
a No indirect costs applied to follow-up costs, since friction cost method was used for indirect costs
b This cost estimate is a mean of detected and undetected values, for both men and women
https://doi.org/10.1371/journal.pone.0221856.t006
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subsequent years. Cost estimates for major stroke were €51,779, €41,868, and €58,289 in the
first years, and for subsequent years €30,234, €24,447, and €16,475.
As is evident from these values, cost estimates for minor stroke, both in the first year and
subsequent years, differed substantially. In contrast, cost estimates for major stroke showed
more agreement. A possible reason for these discrepancies could be the definitions of minor
and major stroke between the studies. Jacobs et al. defined minor stroke as Rankin Scale
(mRS) 1–2, with 3–5 being classified as major stroke. While Greving et al. and Tholen et al.
did not specify their definition, it could be that minor stroke was classified as only mRS 1 in
these studies, resulting in lower costs as a minor stroke would be less severe. This theory is
partly supported by the utilities used in the papers: both in Greving et al. and Tholen et al., the
utility weights for minor stroke were higher than in Jacobs et al. However, as Jacobs et al. uti-
lise a shorter cycle length, comparing utilities in this manner does not produce a definitive
answer.
Stevanović et al. separated stroke into three severities: mild, moderate, and severe. Stevano-
vić et al. and Jacobs et al. both referenced Baeten et al. for costs for stroke. However, the former
did not utilise mRS to determine severity groups.
Table 7. Summary of studies reporting costs for renal failure.
Study Specific type Initial Follow-up Costs covered
Unit cost year 1 in €
(year)
Source(s) Unit cost year 2+ in €
(year)
Source(s) Direct costs Indirect costs
Hunt et al. [24] HD €81,256 (2015) DBC €81,256 (2015) DBC ✓
PD €88,749 (2015) DBC €88,749 (2015) DBC ✓
Renal
transplantation
€49,602 (2015) [66] €2,438 (2015) [66] ✓
Ramos et al. [41] ESRD
hospitalisation
€3,640 (2015) Not specified ✓ ✓
Roze et al. [29] HD €89,447 (2013) Tariffs €89,447 (2013) Tariffs ✓
PD €66,434 (2013) Tariffs €66,434 (2013) Tariffs ✓
Renal
transplantation
€91,503 (2013) Tariffs €3,680 (2013) Tariffs ✓
Van Haalen et al.
[1]
ESRD €69,440 (2011) [67–69] €64,251a (2011) [67] ✓ ✓
Adarkwah et al.
[32]
ESRD €42,110 (2010) [70] ✓
Renal
transplantation
€14,387 (2010) [70] ✓
Dialysis €79,112 (2010) [70] ✓
Home/in-centre HD €83,217 (2010) [70] ✓
CAPD €54,067 (2010) [70] ✓
CCPD €69,546 (2010) [70] ✓
Mazairac et al. [14] HD €86,086 (2009) [71,72], DMC,
hospital
✓ ✓
HDF €88,622 (2009) [71,72], DMC,
hospital
✓ ✓
Boersma et al. [34] Dialysis €72,460 (2008) [73], DMC ✓
CAPD continuous ambulatory peritoneal dialysis, CCPD continuous cycling peritoneal dialysis, DBC diagnosis treatment combination, DMC Dutch manual of costing,
ESRD end-stage renal disease, HD haemodialysis, HDF haemodiafiltration, PD peritoneal dialysis
a no indirect costs applied to follow-up costs, since friction cost method was used for indirect costs
https://doi.org/10.1371/journal.pone.0221856.t007
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While fifteen studies did manage to evaluate resource use and resource costs by means of
questionnaires, record files and databases, eleven studies in this review cited sources predating
2005, some even reporting cost estimates in Dutch guilders instead of euros. Estimates derived
from older papers may give rise to costs not representative of current costs found in healthcare.
Furthermore, this may give rise to a risk of bias, as previous research could be unable to meet
the specifications needed, whereas costs derived from first-hand sources, e.g. hospital records,
are seen as a more accurate reflection.
Although the Dutch guidelines for economic evaluations prefer the societal perspective [6],
only five studies actually took this approach. Moreover, one of these papers explicitly stated
that even though the societal perspective was used, the indirect costs due to lost productivity
losses were not accounted for, because of the advanced age of the patient group [44]. This
means that even though the cost estimate was derived using a societal perspective, it is in fact
an incomplete value, considering travel costs for patients and caregivers are accrued regardless
of patient age. Regarding the other papers, either a hospital perspective or a healthcare per-
spective was used. These perspectives lack direct non-medical costs, such as travel costs, as
well as indirect non-healthcare costs. Therefore, these cost estimates lack societal costs such as
productivity losses.
Tan et al. was the only paper included in this review that compared different costing meth-
odologies [15]. In their paper, bottom-up microcosting, top-down microcosting, and gross
Table 8. Costs for revascularisation.
Study Specified type Initial Follow-up Costs covered
Unit cost year 1 in €
(year)






Ramos et al. [41] PCI €5,951 (2015) Not specified ✓ ✓
CABG €11,304 (2015) Not specified ✓ ✓
Osnabrugge et al.
[40]
PCI €14,037 (2012) Not specified ✓
CABG €17,506 (2012) Not specified ✓
Anastasiadis et al.
[11]
CABG with CECC €18,010 (2012)a Not specified ✓
Heyde et al. [12] PCI same-day
discharge
€4,675 (2006)a Hospital, DMC ✓ ✓
PCI overnight-stay €4,933 (2006)a Hospital, DMC ✓ ✓
Heeg et al. [37] PCI €3,000 (2004) [52,54] ✓
CABG €10,250 (2004) [52,54] ✓
Kauf et al. [30] PCI without stent €12,528 (2002)b Analysts ✓
PCI with stent €13,076 (2002)b Analysts ✓
CABG with CC €37,071 (2002)b Analysts ✓
Van Mastrigt et al.
[19]
CABG €5,441 (2001) DMC, hospital,
questionnaires
✓ ✓
Boersma et al. [33] PCI with stent €4,208 (1999) iMTA ✓
PCI without stent €3,511 (1999) iMTA ✓
Nathoe et al. [39] PCI €4,250 (1999) [55] ✓
CABG €11,472 (1999) [55] ✓
CABG coronary arterial bypass grafting, CC coronary catheterisation, CECC conventional extracorporeal circulation, DMC Dutch manual of costing, iMTA Institute for
Medical Technology Assessment, PCI percutaneous coronary intervention
a No year of costing available, assumed to be the year before publication
b Study reported cost estimates in 2002 USD, converted to 2002 EUR for presentation in the table
https://doi.org/10.1371/journal.pone.0221856.t008
Costs of clinical events in T2DM patients in the Netherlands: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0221856 September 6, 2019 14 / 22
Table 9. Evaluation of the adherence of cost-effectiveness papers to CHEERS.
Checklist item numbers





















































White yes, light grey not applicable dark grey partially, black no, CHEERS Consolidated Health Economic Evaluation Reporting Standards
https://doi.org/10.1371/journal.pone.0221856.t009
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costing were compared, with gross costing differing the most. If other costing studies had spec-
ified their costing methods, it could provide insight into the reason for the heterogeneity
found in cost estimates.
In a systematic review about the costs of treating cardiovascular events in Germany, Schmid
stated that 80–85% of costs in the first year after MI are spent in the first six months, meaning the
other six months of the first year make up for just 15–20% [74]. For the Netherlands, one paper
reported first year cost estimates separated in two periods of six months [37]. They found that the
cost estimates for the first six months were €10,250 and €2,500 for the subsequent six months.
This means that around 80% of the costs in the first year after MI are incurred during the first six
months in the Netherlands, similar to Germany. Comparable findings were found for stroke
events. In the same paper, Schmid reported that in Germany, 80% of the costs for stroke during
the first year were reached within the first half-year. Three papers reported cost estimates for
stroke in the Netherlands in periods of six months [18,26,37]. These studies show that between
69 and 74% of the costs during the first year are incurred in the first half-year. From these results,
it is clear that the larger part of the first-year costs associated with MI and stroke are incurred
within six months of the event. This is to be expected, considering hospitalisation and rehabilita-
tion are the main cost drivers, and are mainly present immediately after an event.
The fact that only three studies reported on the costs associated with TIA illustrates the sys-
tematic underreporting of TIA. It being a transient event, a TIA can go unnoticed, even though
the patient is at a higher risk of other cardiovascular events, or it is grouped with strokes
because of its definition, resulting in an increased number stroke reports, but also decreasing
the average reported costs for stroke [75].
A possible cause for the difference in costs found between studies could be the develop-
ments in healthcare. For example, more efficient or less expensive procedures could have
become the standard. For us, this means that adjusting for inflation would not be enough to
carefully compare costs from 2005 to costs from 2015.
To provide context of the studies in which the costs were used, we also reviewed each study
using the CHEERS checklist. While the majority of CHEERS items focus on more methodo-
logical issues, some items of CHEERS were particularly relevant for this study. These items
were “Estimating resources and costs” and “Currency, price date, and conversion”. Generally,
the first item was well-addressed, while in the latter, some room for improvement was noted,
as either the price date or the conversion method was not mentioned [11,13,16]. However, as
the CHEERS statement was developed as a guideline for the reporting of health economic eval-
uations, the quality of cost estimation cannot be adequately assessed solely with this checklist.
Strengths and limitations
To the best of our knowledge, this is the first systematic review specifically focussing on Dutch
costs of six major T2DM complications. Results can be of relevance for future cost-effective-
ness analyses of new type 2 diabetes treatments in the Netherlands. However, also certain limi-
tations have to be acknowledged. Due to our strict inclusion criteria and focus on major
cardiovascular and renal complications, no attention could be paid to other T2DM-related
events, such as unstable angina, peripheral artery disease, neuropathy, diabetic foot, and reti-
nopathy. Furthermore, the costs associated with micro- and macroalbuminuria were not
explicitly reported, although these cannot be considered as events, but rather as bio-factors or
risk factors for renal events, and if relevant, these were included in the costs for ESRD. Other
T2DM complications are recommended to be included in more comprehensive future studies.
Finally, as most cost estimates reported in the identified studies were based on models or
costs derived from guidelines, instead of trial-based values, the generalisability is limited. This
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means that variance and representativeness of patient samples that make up cost estimates
could not be evaluated. Therefore, our review focussed on a descriptive analysis of our
findings.
Conclusions
This systematic review showed that there is substantial variation in reported cost estimates for
six major complications associated with T2DM. Most of the studies reported on MI and stroke.
Due to a limited amount of papers covering heart failure, revascularization, TIA and renal fail-
ure, cost estimates varied widely and transparency regarding cost sources was generally poor.
The costing of clinical events related to T2DM should be improved and preferably standard-
ised, if accurate and consistent results in economic models are desired.
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